Form 4: Pasithea CFO Acquires 26,667 Shares in Open Market

Pasithea Therapeutics Corp.'s Chief Financial Officer, Daniel H. Schneiderman, acquired 26,667 shares of common stock at $0.75 per share.

Summary

• Daniel H. Schneiderman, Chief Financial Officer of Pasithea Therapeutics Corp. (KTTA), acquired 26,667 shares of the company's common stock.
• The transaction occurred on November 28, 2025, with shares purchased at a price of $0.75 per share.
• Following this acquisition, Mr. Schneiderman directly beneficially owns a total of 26,667 shares of Pasithea Therapeutics Corp. common stock.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a significant insider purchase by the Chief Financial Officer, indicating strong confidence in the company's value and future.

Positives

• The Chief Financial Officer's acquisition of 26,667 shares signals strong insider confidence in the company's future prospects and valuation.
• The direct purchase of common stock aligns management's interests with those of public shareholders.

Industry Context

Insider buying, particularly from a Chief Financial Officer, is often viewed by the market as a positive indicator, suggesting that management believes the company's stock is undervalued or that significant positive developments are anticipated. This transaction occurs within the broader biotechnology and pharmaceutical industry, where investor confidence in a company's pipeline and strategic direction is crucial.

Comparison to Industry Standards

• Insider purchases, especially by key executives like a CFO, are generally considered a stronger signal of confidence compared to purchases by non-executive directors or smaller shareholders.
• The size of the purchase (26,667 shares) represents a notable personal investment by the CFO, which can be interpreted as a significant vote of confidence in Pasithea Therapeutics Corp.'s future performance relative to its peers.

Related Party Transactions

• Chief Financial Officer Daniel H. Schneiderman acquired 26,667 shares of Pasithea Therapeutics Corp. common stock at $0.75 per share on November 28, 2025.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
• Employees might perceive this as a sign of stability and positive future outlook for the company.

Key Dates

Recommendation

The Chief Financial Officer's direct purchase of a substantial number of shares at $0.75 per share is a strong signal of management's belief in the company's intrinsic value and future growth potential. This insider buying activity suggests that the stock may be undervalued, making it an attractive 'buy' for investors seeking to align with informed management sentiment.

Keywords

Pasithea Therapeutics, KTTA, Insider Trading, Form 4, Stock Acquisition, CFO Purchase, Beneficial Ownership, Common Stock